IP(6)-assisted CSN-COP1 competition regulates a CRL4-ETV5 proteolytic checkpoint to safeguard glucose-induced insulin secretion.
IP(6)-assisted CSN-COP1 competition regulates a CRL4-ETV5 proteolytic checkpoint to safeguard glucose-induced insulin secretion.
复制标题
IP6 辅助的 CSN-COP1 竞争调节 CRL4-ETV5 蛋白水解检查点以保护葡萄糖诱导的胰岛素分泌
DOI:
10.1038/s41467-021-22941-3
复制
发表时间:
2021-04-28
影响因子:
16.6
通讯作者:
Rao F
中科院分区:
文献类型:
--
作者:
Lin H;Yan Y;Luo Y;So WY;Wei X;Zhang X;Yang X;Zhang J;Su Y;Yang X;Zhang B;Zhang K;Jiang N;Chow BKC;Han W;Wang F;Rao F
COP1 and COP9 signalosome (CSN) are the substrate receptor and deneddylase of CRL4 E3 ligase, respectively. How they functionally interact remains unclear. Here, we uncover COP1–CSN antagonism during glucose-induced insulin secretion. Heterozygous Csn2WT/K70E mice with partially disrupted binding of IP6, a CSN cofactor, display congenital hyperinsulinism and insulin resistance. This is due to increased Cul4 neddylation, CRL4COP1 E3 assembly, and ubiquitylation of ETV5, an obesity-associated transcriptional suppressor of insulin secretion. Hyperglycemia reciprocally regulates CRL4-CSN versus CRL4COP1 assembly to promote ETV5 degradation. Excessive ETV5 degradation is a hallmark of Csn2WT/K70E, high-fat diet-treated, and ob/ob mice. The CRL neddylation inhibitor Pevonedistat/MLN4924 stabilizes ETV5 and remediates the hyperinsulinemia and obesity/diabetes phenotypes of these mice. These observations were extended to human islets and EndoC-βH1 cells. Thus, a CRL4COP1-ETV5 proteolytic checkpoint licensing GSIS is safeguarded by IP6-assisted CSN-COP1 competition. Deregulation of the IP6-CSN-CRL4COP1-ETV5 axis underlies hyperinsulinemia and can be intervened to reduce obesity and diabetic risk. Mediators of insulin signalling are targets of cullin-RING ubiquitin ligases (CRL) that mediate protein degradation, but the role of protein degradation in insulin signalling is incompletely understood. Here, the authors identified a glucose-responsive CRL4-COP1-ETV5 proteolytic axis that promotes insulin secretion, and is inhibited under hypoglycemia.
登录
查看更多内容
影响因子:
64.5
作者:
Duda, David M.;Borg, Laura A.;Scott, Daniel C.;Hunt, Harold W.;Hammel, Michal;Schulman, Brenda A.
通讯作者:
Schulman, Brenda A.
影响因子:
16.2
作者:
Kim, Sun H.;Reaven, Gerald M.
通讯作者:
Reaven, Gerald M.
影响因子:
5.2
作者:
Erion K;Corkey BE
通讯作者:
Corkey BE
DOI:
10.1146/annurev-pharmtox-010715-103507
发表时间:
2017-01-06
影响因子:
12.5
作者:
Bondeson DP;Crews CM
通讯作者:
Crews CM
影响因子:
8.2
作者:
Gutierrez-Aguilar, Ruth;Kim, Dong-Hoon;Casimir, Marina;Dai, Xiao-Qing;Pfluger, Paul T.;Park, Jongsun;Haller, April;Donelan, Elizabeth;Park, Jisoo;D'Alessio, David;Woods, Stephen C.;MacDonald, Patrick E.;Seeley, Randy J.
通讯作者:
Seeley, Randy J.